Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Empagliflozin treatment of cardiotoxicity: A comprehensive review of clinical, immunobiological, neuroimmune, and therapeutic implications
Zahra Vaziri, Kiarash Saleki, Cena Aram, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 168, pp. 115686-115686
Open Access | Times Cited: 11

Showing 11 citing articles:

In Silico Design and Molecular Dynamics Analysis of Imidazole Derivatives as Selective Cyclooxygenase-2 Inhibitors
Mohamed J. Saadh, Hanan Hassan Ahmed, Radhwan Abdul Kareem, et al.
Computational Biology and Chemistry (2025) Vol. 115, pp. 108341-108341
Closed Access
Acute and Chronic Cardiovascular Adverse Events in Patients with Acute Myeloid Leukemia: A Systematic Review
Konstantinos C. Siaravas, Amalia Ioanna Moula, Ioannis S. Tzourtzos, et al.
Cancers (2025) Vol. 17, Iss. 3, pp. 541-541
Open Access
Sodium–glucose cotransporter 2 inhibitors and the cancer patient: from diabetes to cardioprotection and beyond
Massimiliano Camilli, Marcello Viscovo, Luca Maggio, et al.
Basic Research in Cardiology (2024)
Open Access | Times Cited: 4
Risks and Benefits of SGLT-2 Inhibitors for Type 1 Diabetes Patients Using Automated Insulin Delivery Systems—A Literature Review
Viviana Elian, Violeta Popovici, Oana Karampelas, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 4, pp. 1972-1972
Open Access | Times Cited: 2
Gut Microbiota to Microglia: Microbiome Influences Neurodevelopment in the CNS
Jeffery Bettag, Daniel Goldenberg, Jasmine Carter, et al.
Children (2023) Vol. 10, Iss. 11, pp. 1767-1767
Open Access | Times Cited: 6
Cardioprotective Potential of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Cancer Treated With Anthracyclines: An Observational Study
Ayman R. Fath, Mostafa Aglan, Amro Aglan, et al.
The American Journal of Cardiology (2024) Vol. 222, pp. 175-182
Closed Access | Times Cited: 1
Nocturnal blood pressure and left ventricular hypertrophy in patients with diabetes mellitus
Yasutomi Higashikuni, Wenhao Liu, Masataka Sata
Hypertension Research (2023) Vol. 47, Iss. 3, pp. 819-822
Open Access | Times Cited: 2
Why have SGLT2 Inhibitors Failed to Achieve the Desired Success in COVID-19?
Medine Cumhur Cüre, Erkan Cüre
Current Pharmaceutical Design (2024) Vol. 30, Iss. 15, pp. 1149-1156
Closed Access
Effects of Sitagliptin versus Empagliflozin on the Stress Hyperglycemic Ratio in People with Type 2 Diabetes: An Open-Label, Randomized Controlled Trial
Marwan S.M. Al-Nimer, Ismail Ibrahim Latif, Thaqeef Murtada Jawad
Clinical Diabetology (2024) Vol. 13, Iss. 3, pp. 156-163
Open Access
Bibliometric and visual analysis of SGLT2 inhibitors in cardiovascular diseases
Rongfang Pan, Yuqing He, Wan Melisandre, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access
Empagliflozin improves pressure-overload-induced cardiac hypertrophy by inhibiting the canonical Wnt/β-catenin signaling pathway
Xun Yuan, Pan Li, Chi Zhang, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access
Page 1

Scroll to top